

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4382052

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
LIANSHENG LI	04/18/2017
JUN FENG	04/24/2017
YUN OLIVER LONG	04/19/2017
PINGDA REN	04/18/2017
YI LIU	04/18/2017
RECEIVING PARTY DATA	
Name:	ARAXES PHARMA LLC
Street Address:	11119 N. TORREY PINES ROAD
Internal Address:	SUITE 125
City:	LA JOLLA
State/Country:	CALIFORNIA
Postal Code:	92037
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15508387
CORRESPONDENCE DATA	
Fax Number:	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	650-461-5211
Email:	cricks@wsgr.com
Correspondent Name:	CHRISTINE RICKS
Address Line 1:	650 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304-1050
ATTORNEY DOCKET NUMBER:	43683-712.831
NAME OF SUBMITTER:	CHRISTINE RICKS
SIGNATURE:	/Christine Ricks/
DATE SIGNED:	04/24/2017
Total Attachments: 1	

PATENT ASSIGNMENT

Docket Number 43683-712.831

WHEREAS, the undersigned:

- 1. LI, Liansheng
San Diego, CA
- 2. FENG, Jun
San Diego, CA
- 3. LONG, Yun Oliver
San Diego, CA
- 4. REN, Pingda
San Diego, CA
- 5. LIU, Yi
San Diego, CA

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in

METHODS AND COMPOSITIONS FOR INHIBITION OF RAS

for which Application No. 15/508,387 was submitted on March 2, 2017 to the USPTO as a National Phase entry of an international application filed on September 25, 2015; (hereinafter "Application(s)").

WHEREAS, Araxes Pharma LLC, a Limited Liability Company of the State of Delaware, having a place of business at 11119 N. Torrey Pines Rd. Ste 125, La Jolla, CA 92037, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s) and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter "Patent(s)") thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions, including the right to claim priority to said Inventions; (b) in and to all rights to all United States and corresponding non-United States patent applications and Patent(s), including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise; (c) in and to any and all applications filed and any and all Patent(s) granted on said Inventions in the United States, in any foreign country, or under any international convention, agreement, protocol, or treaty, including each and every application filed and any and all Patent(s) granted on any application which is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); and (d) in and to each and every reissue, reexamination, or extensions of any of said Patent(s).
2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.
3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.
4. Said Inventor(s) hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: 04/18/2017 [Signature]
Liansheng Li

Date: 4/19/17 [Signature]
Yun Oliver Long

Date: 4/18/2017 [Signature]
Yi Liu

Date: 4/24/2017 [Signature]
Jun Feng

Date: 4/18/2017 [Signature]
Pingda Ren

RECEIVED AND AGREED TO BY ASSIGNEE:
Date: 4/24/2017

Araxes Pharma LLC
Signature: [Signature]
Name/Title: Annette North/Secretary and General Counsel